Seeking Alpha
View as an RSS Feed

Mars Report  

View Mars Report's Comments BY TICKER:

Latest  |  Highest rated
  • How I'm Playing The Next Wave Of Creative Destruction [View article]
    The attention surrounding both the stock and product are certainly mounting, especially now that the product is available.

    In regards to the financials, the company currently has $2.4 million in cash with approximately 600K in liabilities. The company anticipates to have a quarterly burn rate of approx. 300-400K. So at a minimum the company has enough cash until the end of 2014. Of particular importance, the launch of the app now allows the company to begin realizing the sales they anticipate, which will drive revenue and bolster the cash position.
    Dec 13, 2013. 05:25 PM | Likes Like |Link to Comment
  • Introducing The New And Improved Implant Sciences [View article]
    Good point Fincher,

    However, in regards to the financing concern, I anticipate a restructured agreement from the companies primary financier, the DMRJ Group. They've done it in the past (earlier this year actually when the prospects for the company were not as vast as they are now. It simply wouldn't equate for them not to extend credit, as the product is on the verge of yielding promising returns. It's much easier to justify extending credit at this point, than any other point in the companies history.
    Oct 18, 2013. 11:48 AM | 2 Likes Like |Link to Comment
  • How Car Charging Group Is Utilizing Tesla's Publicity [View article]
    The intent and focus of this article is geared towards the increase in visibility the company shall see from the momentum and appreciation in price Tesla has witnessed, with the EV industry benefiting in a parallel sequence.

    Please refer to my previous articles for a more in-depth analysis of CCGI and EV infrastructure developers:

    Please see the "Consolidated Payment System" subsection in the article which highlights a potential solution to the issue you addressed of users being necessitated to carry multiple cards to charge their vehicles on an array of networks. If you yourself suffer from this problem, you'll be pleased to know efforts are underway to universalize the cloud system by 2014.
    Jul 29, 2013. 05:59 PM | 2 Likes Like |Link to Comment
  • PerkinElmers' Collaboration: Testimony To The Strength Of Trovagene's Novel Technology Platform [View article]
    Thanks for the comment Niksurfs,

    The implications of PerkinElmers exposure in South East Asia stretches far beyond the potential production & deployment of the HCC assay alone. A majority of the diagnostics the company sells in China currently screen for infectious diseases and prenatal genetic disorders, which is one of the fastest-growing diagnostics markets.
    Assuming the collaboration for the development of the HCC assay bodes well with PerkinElmer, focus could tranistion to manufacturing and marketing Trovagene's TrNA technology (for cost-effictive, ease-of-use alternatives), which is already feasible considering the company already has a commercially available version of an HPV test.
    Apr 26, 2013. 05:56 PM | Likes Like |Link to Comment
  • Trovagene Advances Next-Gen Version Of Qiagen's HPV Test [View article]
    The sales figures will come with time and progression. The market has underrated the enormous implications of commercializing a patented urine-based HPV screening test and your correct in noting that institutional attention will garner validity as well as liquidity and appreciation in the PPS.

    If the market and institutions fail to recognize the potential of the HPV test before the end of Q2, the KRAS mutation assay launch may host the attention the company deserves. Until then, the stock price of mid-5's to low-6's offers new investors an attractive entry point or current investors already following the company to average down.
    Apr 12, 2013. 12:54 PM | 1 Like Like |Link to Comment
  • Trovagene Advances Next-Gen Version Of Qiagen's HPV Test [View article]
    Thanks for the interest RogerAH,

    I'm surprised the market has granted an elongated window of opportunity for new investors to jump in. It's ironic how traders bought the hype of the company and sold the news of the HPV-assay for a short term profit. Once sales figures appear domestically and abroad (potential in India and Brazil) for the HPV-test, I believe its imminent that a licensing deal with be achieved at minimum. That, along with diverse pipeline of diagnostic test advancements will propel the pps higher over the long term (over 2013) not to mention the possiblity of shorts covering their position in the short term.
    Apr 11, 2013. 03:07 PM | 1 Like Like |Link to Comment